---
title: "Gracell 生物技术股东批准阿斯利康合并协议。"
description: "Gracell 生物技术股东已经批准与阿斯利康的合并协议。该协议涉及合并的执行、交付和履行，使 Gracell 成为阿斯利康的全资子公司。此次批准获得了会议上投票总数的 99.9% 支持。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/108247711.md"
published_at: "2024-02-20T13:00:42.000Z"
---

# Gracell 生物技术股东批准阿斯利康合并协议。

> Gracell 生物技术股东已经批准与阿斯利康的合并协议。该协议涉及合并的执行、交付和履行，使 Gracell 成为阿斯利康的全资子公司。此次批准获得了会议上投票总数的 99.9% 支持。

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, announced today that during an extraordinary general meeting of shareholders (EGM) on February 19, 2024, shareholders voted in favor of the proposal to approve and authorize the execution, delivery, and performance of the Agreement and Plan of Merger. This agreement, dated December 23, 2023 (the "Merger Agreement"), involves the Company, AstraZeneca Treasury Limited, a private limited company incorporated in England and Wales ("Parent"), and Grey Wolf Merger Sub, a wholly owned subsidiary of Parent incorporated in the Cayman Islands ("Merger Sub"). The approval also covers the Plan of Merger to be filed with the Registrar of Companies of the Cayman Islands, as well as any other agreements or documents related to the Merger Agreement or delivered in connection with it. 根据并购协议约定的条款和条件，包括并购协议（包括合并）和附表 B 所附的《附带价值权协议》，（统称为 “交易”），公司作为一方参与了 “行动文件”，并完成了所 contempl 的交易。根据并购协议，根据开曼群岛《公司法（修订版）》的适用规定，Merger Sub 将在合并的生效时间与公司合并，公司将继续作为存续公司，并成为母公司的全资子公司（“合并”）。

公司总共 458,283,333 股普通股，每股面值为$0.0001（“普通股”），包括公司的美国存托股（“ADSs”），出席了 EGM，不论亲自出席还是通过代理出席。每位股东每股普通股有一票。这些股份约占公司在开曼群岛营业结束时所持有的普通股总数的 94.8%。 在 2024 年 1 月 8 日的股东大会记录日期上，大约 99.9% 的总投票数赞成《合并协议》、《合并计划》和相关交易。

### Related Stocks

- [AZN.US - 阿斯利康](https://longbridge.com/zh-CN/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients | AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients | [Link](https://longbridge.com/zh-CN/news/276444179.md) |
| AstraZeneca PLC $AZN Shares Sold by Ontario Teachers Pension Plan Board | Ontario Teachers Pension Plan Board reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 41% in Q3, now holding 817,880  | [Link](https://longbridge.com/zh-CN/news/276339476.md) |
| Do Wall Street Analysts Like Ecolab Stock? | Do Wall Street Analysts Like Ecolab Stock? | [Link](https://longbridge.com/zh-CN/news/276322789.md) |
| Daiichi Sankyo and AstraZeneca get EU validation for Enhertu use | Daiichi Sankyo and AstraZeneca have received validation from the European Medicines Agency for their application to exte | [Link](https://longbridge.com/zh-CN/news/276408087.md) |
| 10:12 ETThe Michael J. Fox Foundation Releases New Care Partner Guide to Support Families Living with Parkinson's | The Michael J. Fox Foundation has released a new digital guide titled "Facing Parkinson's Together" to support care part | [Link](https://longbridge.com/zh-CN/news/276457960.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。